New JN.1 vaccine trial aims to boost protection against latest COVID variant

NCT ID NCT07079670

First seen Feb 21, 2026 · Last updated May 14, 2026 · Updated 14 times

Summary

This study tests a new vaccine designed to protect against the Omicron JN.1 variant of COVID-19. About 120 adults aged 65 and older, or those aged 12-64 with health conditions that raise their risk, will receive one shot. Researchers will check how well the vaccine boosts immunity and monitor safety for 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number US047

    Austin, Texas, 78705-3298, United States

  • Investigational Site Number US073

    Tomball, Texas, 77375, United States

  • Investigational Site Number US294

    Lafayette, Louisiana, 70508, United States

  • Investigational Site Number US326

    Omaha, Nebraska, 68134, United States

  • Investigational Site Number US381

    Cincinnati, Ohio, 45246-2316, United States

  • Investigational Site Number US391

    Pleasant View, Utah, 84404-4791, United States

  • Investigational Site Number US395

    Melrose Park, Illinois, 60160, United States

  • Investigational Site Number US404

    Phoenix, Arizona, 85044, United States

  • Investigational Site Number US406

    Lenexa, Kansas, 66219, United States

  • Investigational Site Number US407

    Southfield, Michigan, 48076-5412, United States

Conditions

Explore the condition pages connected to this study.